1. Date of download: 6/23/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Refractive Outcomes Following Bevacizumab Monotherapy Compared With Conventional Laser Treatment: A Randomized Clinical Trial JAMA Ophthalmol. 2014;132(11):1327-1333. doi:10.1001/jamaophthalmol.2014.2772 Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity (BEAT-ROP) Infants were stratified by ROP zone and randomized between 2 treatment modalities: intravitreal bevacizumab (treatment group) and laser treatment (control group). a One infant who died had undergone bilateral vitrectomy. b Nonaccidental trauma. Figure Legend:

2. Date of download: 6/23/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Refractive Outcomes Following Bevacizumab Monotherapy Compared With Conventional Laser Treatment: A Randomized Clinical Trial JAMA Ophthalmol. 2014;132(11):1327-1333. doi:10.1001/jamaophthalmol.2014.2772 Zone I Distribution of Refractive Error by Treatment ModalityDistribution of spherical equivalent refractive error at age 2½ years in eyes that received treatment for stage 3+ retinopathy of prematurity or aggressive posterior retinopathy of prematurity in the Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity clinical trial. Data are presented according to treatment modality. Figure Legend:

3. Date of download: 6/23/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Refractive Outcomes Following Bevacizumab Monotherapy Compared With Conventional Laser Treatment: A Randomized Clinical Trial JAMA Ophthalmol. 2014;132(11):1327-1333. doi:10.1001/jamaophthalmol.2014.2772 Zone II Posterior Distribution of Refractive Error by Treatment ModalityDistribution of spherical equivalent refractive error at age 2½ years in eyes that received treatment for stage 3+ retinopathy of prematurity or aggressive posterior retinopathy of prematurity in the Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity clinical trial. Data are presented according to treatment modality. Figure Legend:

4. Date of download: 6/23/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Refractive Outcomes Following Bevacizumab Monotherapy Compared With Conventional Laser Treatment: A Randomized Clinical Trial JAMA Ophthalmol. 2014;132(11):1327-1333. doi:10.1001/jamaophthalmol.2014.2772 Percentage of Eyes at −5 Diopters or Greater in the Early Treatment for Retinopathy of Prematurity (ETROP) Compared With Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity (BEAT-ROP) TrialsEvaluations were conducted at ages 3 years (ETROP) and 2½ years (BEAT-ROP). Data are presented in ETROP according to ROP severity at treatment and in BEAT-ROP according to the treatment modality used. Figure Legend: